The "Molecular Switch Targeting Therapies Market Landscape, Innovation Pipeline and Commercial Impact 2026" report has been added to ResearchAndMarkets.com's offering. The report is designed to give ...

A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

Hydrocephalus is a life-threatening condition that occurs in about 1 in 1,000 newborns and is often treated with invasive ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...

One of the persistent challenges in precision oncology is the fact that most advanced cancers are complex and highly individualized. A recent ...

Molecular response to therapy in early-stage PV patients correlates with improved event-free survival outcomes. Ropeginterferon alfa-2b significantly reduces JAK2V617F variant allele frequency, ...

Recombinant immunotoxins represent a sophisticated class of biotherapeutics that combine the targeting specificity of antibody fragments with the potent cytotoxic effects of bacterial or plant toxins.

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they were foreign invaders. This widespread category of illnesses, such as ...